Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical
technology business, proudly supports results of an independent,
randomised clinical trial1 concluding that, in the patients
studied, the use of the PICO Single Use Negative Pressure Wound
Therapy (NPWT) system significantly reduced the rate of surgical
site infections (SSI) by 74%, compared to standard care in patients
undergoing major abdominal incisions.
The randomized, controlled, open-label trial of 50 patients
investigated the role of PICO Single Use NPWT used prophylactically
in patients undergoing major abdominal surgery. Thirty days after
operations, the incidence rates of SSI significantly reduced by 74%
(8.3% in treatment group vs. 32% in control group). Patients’
length of stay also reduced by approximately eight days (6.1 vs.
14.7 days). The treatment group included the use of the PICO Single
Use NPWT system.
The PICO Single Use NPWT system is indicated for patients at
risk of poor healing as it can help to improve the speed, strength
and quality of incisional wound closure, and may minimise the
failures of healing that may lead to infection and/or dehiscence2.
The PICO system is suitable for use in both a hospital and
community setting and approved for a number of indications,
including surgically closed incision sites.
“This study underscores the importance of PICO Single Use NPWT
in treating patients who have undergone a laparotomy (open
abdominal surgery),” said Colin Peirce, Consultant General and
Colorectal Surgeon, University Hospital Limerick, Ireland. “As
surgeons, we are always looking for effective and cost efficient
ways to treat patients, and this study demonstrates that PICO
Single Use NPWT can significantly reduce both the incidence of
surgical site infection and the length of stay, resulting in a
potential reduction in healthcare costs,” concludes Colin
Pierce.
Up to 60% of all SSIs are preventable but they continue to be a
large burden on the healthcare system3. With approximately 500,000
SSIs per year in the US and 8,000 connected annual deaths, the cost
of SSIs are in excess of $7 billion and over £758 million per year
in the UK3.
“This study is the latest addition of research that reinforces
the importance of PICO Single Use NPWT and the significant impact
it has on reducing SSIs, healthcare costs and ultimately improving
the patient’s quality of life,” said Andy Weymann, Chief Medical
Officer in Smith & Nephew. “It follows the recent release of
global guidelines from the World Health Organisation (WHO)
recommending the use of NPWT prophylactically,” added Andy
Weymann.
The PICO Single Use NPWT system is being investigated in a
number of clinical trials worldwide. For more information about the
clinical trials, please visit: www.clinicaltrials.gov.
- Ends -
™ Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office
About Negative Pressure Wound Therapy (NPWT)
Negative Pressure Wound Therapy (NPWT) has been in use for more
than 20 years for the management of a wide range of different wound
types in adults, including traumatic hard-to-heal and chronic
wounds, and wounds covered with flaps and/or skin grafts. It has
also been used for the management of complex wounds. More recently,
NPWT systems have been used to manage closed surgical incisions in
patients at high risk of surgical site complications.
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports
Medicine and Trauma & Extremities, Smith & Nephew
has around 15,000 employees and a presence in more than 100
countries. Annual sales in 2016 were more than $4.6 billion. Smith
& Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit
our website www.smith-nephew.com, follow @SmithNephewplc on
Twitter or visit SmithNephewplc on Facebook.com.
To learn more about what we do to help reduce surgical site
complications, please visit www.closertozero.com.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
Reference:
1. O’Leary, D.P. et al, Prophylactic negative pressure dressing
use in closed laparotomy wounds following abdominal operations. A
randomized, controlled, open-label trial: The PICO Trial. Annals of
Surgery, published online 06 December 2016.
2. S. Karlakki, M. Brem, S. Giannini, V. Khanduja, J. Stannard,
R. Martin. Negative pressure wound therapy for management of the
surgical incision in orthopaedic surgery. Bone Joint Res
2013;2:276–84.
3. World Union of Wound Healing Societies (WUWHS) Consensus
Document. Closed surgical incision management: understanding the
role of NPWT. Wounds International, 2016
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170516005157/en/
MadanoKarley Ura+44 (0) 20 3595 2415orJaclyn Confalone+44 (0) 20
3595 2441orSmith & NephewDave Snyder+1 (978) 749-1440
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Sep 2023 to Sep 2024